New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease
Site Search
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations
Today, the Cystic Fibrosis Foundation awarded $2.76 million for 11 laboratory studies that will advance our understanding of the underlying factors that impact COVID-19 outcomes in people with cystic fibrosis. Ultimately, insights gained from this body of research may be used to improve future treatments.
The Foundation’s award will support preclinical studies of a potential phage therapy to treat resistant Pseudomonas infections.
Study reaffirms the Foundation's commitment to advance solutions to the growing challenge of antibiotic resistance and evaluate the use of phage to treat infections for people with CF
This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.